Premium
Crossover Trial of Mazindol for Cocaine Dependence
Author(s) -
Kosten Thomas R.,
Steinberg Marlene,
Diakogiannis Ionas A.
Publication year - 1993
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1111/j.1521-0391.1993.tb00216.x
Subject(s) - mazindol , crossover study , craving , placebo , cocaine dependence , crossover , methadone , anesthesia , dopamine , psychology , medicine , dopamine agonist , pharmacology , addiction , psychiatry , computer science , alternative medicine , dopaminergic , pathology , artificial intelligence
Mazindol, an indirect dopamine agonist, was given at 2 mg qd to 19 cocaine‐dependent, methadone‐maintained patients during a 2‐week, placebo‐controlled, crossover trial. Patients showed no significant reduction in cocaine use, but they had increased cocaine craving on mazindol compared with placebo.